Application value of Mycobacterium bovis lipopolysaccharide in the serological diagnosis of tuberculosis in animals

doi:10.19982/j.issn.1000-6621.20220496

Abstract

Abstract:

Objective: To evaluate the clinical application of Mycobacterium bovis (M.bovis) lipopolysaccharide in the serological diagnosis of tuberculosis in animals. Methods: Bioactive lipopolysaccharides were extracted from inactivated M.bovis, and tested using enzyme linked immunosorbent assay (ELISA) to detect negative bovine sera and positive bovine sera for tuberculosis, paratuberculosis, brucellosis, foot-and-mouth disease, chlamydiosis and neosporosis, to determine the specificity of lipopolysaccharides for the diagnosis of animal tuberculosis. Meanwhile, 245 bovine serum samples (177 were positive and 68 were negative for tuberculin skin test (TST)), 29 plum deer serum samples (10 were positive and 19 were negative for TST) and 14 roe deer serum samples (all positive for TST) were collected. The antibody levels were measured by ELISA, and the TST results were used as a reference to evaluate the clinical application of lipopolysaccharide in the serological diagnosis of tuberculosis in animals. Results: Except for the tuberculosis positive bovine sera, the results of the positive diseased bovine sera were not statistically different from those of the negative bovine sera (P>0.05) and were lower than the Cut off values. The overall compliance of the ELISA antibody assay based on lipopolysaccharide with the TST results was 88.54% (255/288), the overall sensitivity was 87.56% (176/201), and the overall specificity was 90.80% (79/87). Conclusion: M.bovis lipopolysaccharide can be used as one of the specific antigens for the serological diagnosis of animal tuberculosis, it helps to improve the specificity and detection rate of existing diagnostic methods, and has good application value.

Key words: Mycobacterium bovis, Lipopolysaccharides, Tuberculosis, Serologic tests

CLC Number:

R52
R522.2

Wang Yuanzhi, Long Meizhen, Liu Yiduo, Zhou Xiangmei. Application value of Mycobacterium bovis lipopolysaccharide in the serological diagnosis of tuberculosis in animals[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 401-405. doi: 10.19982/j.issn.1000-6621.20220496

Figures/Tables 3

References 12

[1]	徐彩红, 周向梅, 范伟兴, 等. 人畜禽共患结核病防控现状及展望. 中国防痨杂志, 2021, 43(10):993-997. doi:10.3969/j.issn.1000-6621.2021.10.003. doi: 10.3969/j.issn.1000-6621.2021.10.003
[2]	Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria. Int J Tuberc Lung Dis, 2006, 10(11):1192-1204. pmid: 17131776
[3]	张灵霞, 李国利, 陈彭, 等. 结核多糖对结核病诊断价值的研究. 山西医药杂志(下半月刊), 2013, 42(9):1058-1059. doi:10.3969/j.issn.0253-9926.2013.18.064. doi: 10.3969/j.issn.0253-9926.2013.18.064
[4]	Nigou J, Gilleron M, Puzo G. Lipoarabinomannans:from structure to biosynthesis. Biochimie, 2003, 85(1/2):153-166. doi:10.1016/s0300-9084(03)00048-8. doi: 10.1016/s0300-9084(03)00048-8 URL
[5]	Broger T, Tsionksy M, Mathew A, et al. Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. PLoS One, 2019, 14(4):e0215443. doi:10.1371/journal.pone.0215443. doi: 10.1371/journal.pone.0215443
[6]	Nkereuwem E, Togun T, Gomez MP, et al. Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study. Lancet Infect Dis, 2021, 21(3):376-384. doi:10.1016/S1473-3099(20)30598-3. doi: 10.1016/S1473-3099(20)30598-3 pmid: 33316214
[7]	Niculescu D, Stefănoiu V, Stavri H, et al. Serodiagnosis of extrapulmonary tuberculosis by enzyme-linked immunosorbent assay (ELISA). Roum Arch Microbiol Immunol, 1999, 58(2):111-119. pmid: 11845450
[8]	Lyashchenko K, Colangeli R, Houde M, et al. Heterogeneous antibody responses in tuberculosis. Infect Immun, 1998, 66(8):3936-3940. doi:10.1128/IAI.66.8.3936-3940.1998. doi: 10.1128/IAI.66.8.3936-3940.1998 pmid: 9673283
[9]	李倩钰, 徐鹏, 陈玲. 活动性结核病候选血清学诊断标志物的研究进展. 实用心脑肺血管病杂志, 2021, 29(6):17-21. doi:10.12114/j.issn.1008-5971.2021.00.125. doi: 10.12114/j.issn.1008-5971.2021.00.125
[10]	World Health Organization. High-Priority Target Product Profiles for New Tuberculosis Diagnostics:Report of a Consensus Meeting. Geneva: World Health Organization, 2014.
[11]	张舒林, 王洪海. 结核分枝杆菌特异性抗原检测的研究现状及展望. 中国热带医学, 2008, 8(2):299-301.
[12]	Sigal GB, Pinter A, Lowary TL, et al. A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-XylofuranoseLipoarabinomannan Epitope Meets the WHO’s Performance Target for Tuberculosis Diagnosis. J Clin Microbiol, 2018, 56(12):e01338-18. doi:10.1128/JCM.01338-18. doi: 10.1128/JCM.01338-18

脂多糖包被浓度	血清稀释比例
脂多糖包被浓度	不稀释	1∶10	1∶20	1∶40
10.00μg/ml
阳性血清A₄₅₀值(P)	0.236	0.493	0.488	0.366
阴性血清A₄₅₀值(N)	0.140	0.142	0.124	0.119
P/N值	1.690	3.470	3.940	3.080
5.00μg/ml
阳性血清A₄₅₀值(P)	0.196	0.276	0.333	0.431
阴性血清A₄₅₀值(N)	0.149	0.132	0.124	0.193
P/N值	1.320	2.090	2.690	2.230
2.50μg/ml
阳性血清A₄₅₀值(P)	0.235	0.257	0.354	0.306
阴性血清A₄₅₀值(N)	0.136	0.118	0.122	0.134
P/N值	1.730	2.180	2.900	2.280
1.25μg/ml
阳性血清A₄₅₀值(P)	0.305	0.186	0.130	0.129
阴性血清A₄₅₀值(N)	0.112	0.109	0.114	0.124
P/N值	2.720	1.710	1.140	1.040

检测指标	阴性	结核病	副结核病	布鲁氏菌病	口蹄疫	衣原体病	新孢子虫病
A₄₅₀值	0.178	0.699	0.185	0.175	0.182	0.147	0.173
	0.175	0.725	0.164	0.169	0.191	0.196	0.192
	0.183	0.929	0.181	0.171	0.175	0.177	0.163
	0.153	0.963	0.185	0.177	0.184	0.160	0.176
	0.174	0.849	0.172	0.161	0.165	0.187	0.177
	0.204	0.918	0.161	0.189	0.170	0.186	0.172
平均值	0.178	0.847	0.175	0.174	0.178	0.176	0.176
标准差	0.015	0.102	0.010	0.009	0.009	0.017	0.009
P值		<0.001	0.748	0.641	0.930	0.868	0.824

[1]	Zhao Aihua, Du Weixin, Wang Guozhi, Xu Miao. Discussion on the nomenclature of recombinant Mycobacterium tuberculosis allergen skin test [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 333-335.
[2]	Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
[3]	Teng Rencong, Li Tao, LI Yuhong, Yang Chenlu, Zhang Canyou, Zhao Yanlin, Zhang Hui. Analysis of registration records of elderly pulmonary tuberculosis patients aged 65 and above in China,2015—2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 367-371.
[4]	Wu Tana, Li Yuhong, Liu Xiaoqiu. Study on the feasibility of active tuberculosis screening strategy for the elderly based on public health service [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 372-376.
[5]	Zhang Pei, Zhao Ahui, Gao Min, Zhen Xinan, Yao Yuxia, Jiang Jianguo, Sun Jianwei, Sun Dingyong. Epidemiological characteristics of MTB/HIV co-infection in Henan from 2016 to 2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 377-382.
[6]	Mao Hongkai, Zhang Yan, Liang Zhichao, Xia Wenjun, Bao Liangliang, Mayisha·Daken , Wang Xiaomin, Cao Mingqin. Evaluation of implementation effect of pulmonary tuberculosis prevention and control strategy in southern Xinjiang based on synthetic control method [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 383-390.
[7]	Duan Yuheng, Zhang Lanyue, Dong Jing, Shi Yuting, Jia Hongyan, Li Zihui, Xing Aiying, Du Boping, Sun Qi, Pan Liping, Zhu Chuanzhi, Zhang Zongde. Effects of acetyltransferase fadA3 on acetylation of host protein and in vivo survival of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 391-400.
[8]	Zhu Yumei, Xia Zihan, Li Jinli, He Huishan, Wang Feng. Application value of multicolor melting curve analysis in detection of pre-extensive drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 406-411.
[9]	Lai Min, Wu Guihui, Chen Hongde, Cheng Yao, Luo Haixia, He Kejing. Clinical characteristics and maternal and infant outcomes of 13 pregnant women with rifampicin resistant and multidrug resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 412-419.
[10]	Zhou Weidong, Zhang Zhengdong, Lin Mei, Li Tongxia. Progress in diagnosis and treatment of Mycobacterium avium-intracellular complex vertebral osteomyelitis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 420-425.
[11]	Wang Wenjing, Sun Hong, Sun Zhaogang. Progress of innate immune mechanism activated by Mycobacterium tuberculosis DNA-mediated pattern recognition receptors [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 426-433.
[12]	Zou Yuanwu, Li Jing, Wang Biao, Wang Zhuo, Qu Shaoyi, Yuan Zhimin, Wu Qianhong. The diagnostic value of simultaneous amplification and testing for Mycobacterium tuberculosis technique on alveolar lavage fluid for diagnosing pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 434-436.
[13]	The Group of Osteoarticular Tuberculosis of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on the application of the concept of enhanced recovery after surgery in spinal tuberculosis surgery [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 225-234.
[14]	Jia Fei, Cao Yanlin, Jiang Shiwen, Zhang Ke, Yi Min. Comparison and enlightenment of international legislation experience on tuberculosis control [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 235-239.
[15]	Zhang Ke, Cao Yanlin, Jiang Shiwen, Chen Mingting, Jia Fei, Yi Min. Analysis of the current situation of local legislation on tuberculosis prevention and control in China [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 240-243.